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INTRODUCTION	  
Obesity	  and	  Diabetes	  	  
 
 Since 1980 the prevalence of obesity (Body Mass Index (BMI) ≥30 kg/m2) has 
nearly doubled from 13% of adults aged 20+ to todays average of over 24% percent of 
adults aged 20+, worldwide (1). Adverse metabolic effects such as increased blood 
pressure, triglycerides, cholesterol, and insulin resistance are often associated with 
obesity. Risk of certain cancer incidences such as breast, prostate, endometrium, kidney, 
colon, and gall bladder have shown to increase as BMI increases as well. An approximate 
35.8 million (2.3%) of global disability adjusted life years (DALYs) are caused as a result 
of being overweight/obese and more than 2.8 million people die each year as a direct 
result (1) . 
 The onset of type 2 diabetes begins when the body develops sensitivity to insulin. 
Insulin is an important hormone secreted by the pancreas’ beta cells to facilitate the 
transfer of postprandial blood glucose from the blood stream into cells. If more sugar is 
consumed than the body needs, insulin aids in storing the excess glucose in the liver. 
Overtime, continual exposure to an abundance of glucose can cause the beta cells to 
become desensitized causing a drastic decrease or potentially stopping the production of 
insulin all together. Without insulin, cells cannot uptake glucose from the blood stream to 
be used as fuel and the body will need to enter ketosis to maintain an energy supply. 
Prolonged exposure to excess sugar in the blood stream and ketosis will eventually lead 
to multiple organ failure and, if untreated, death (2). 
 Research has found that genes play a larger role in the connection between the 
immune system, metabolism, and environment than previously thought. This complex 
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connection has shown to alter the outcome of body weight, influencing energy 
expenditure, appetite, and many finite metabolic functions (3-5). Despite these metabolic 
predispositions that may help to facilitate obesity, genetics alone cannot explain the 
increased incidence of obesity associated with the consumption of a Western diet (e.g. 
high in glucose, fructose, sucrose, saturated fats, and empty carbohydrates).    
Acetate	  Consumption	  and	  Increased	  Insulin	  Secretion	  
 
Short chain fatty acids (SCFAs) are the main products of fermentation. Acetate, 
propionate, and butyrate are produced when dietary fibers are fermented by anaerobic 
colonic microbiota (6). Recently research has looked at the role these SCFAs play in the 
health of our gut and has found a link between increased acetate production and obesity. 
A study conducted by Perry et al. examined glucose-stimulated insulin secretion (GSIS) 
during a hyperglycemic clamp. Perry and her team wanted to examine whether increases 
in acetate turnover drove an increase in GSIS. To do this they performed hyperglycemic 
clamps in chow fed rats given intra-arterial infusions of acetate matching that of the 
whole body turn over of acetate measured in high fat diet (HFD) fed rats. The rats fed the 
acetate infusion showed similar increases in GSIS to that of the rats fed the HFD. Going 
further, when replacing the butyrate turnover to levels compared to that in the HFD rats 
they found there was no effect on GSIS. This research suggests increased acetate turnover 
has the ability to drive insulin secretion (7). 
	   The	  Gut	  Microbiota	  
 
 The human gastrointestinal (GI) tract’s ecosystem is primarily composed of 
bacteria. The colon has the highest density of cells that has ever been demonstrated in any 
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ecosystem (1011-1012/mL contents). Bacteroidetes (48%) and Firmicutes (51%) are two 
phylums of bacteria that make up the majority of the inhabitants (8). The human gut 
microbiota consists of 1013 to 1014 microorganisms. These bacteria are mutually beneficial 
for the host organism, utilizing their ability to break down ingested polysaccharides into 
monosaccharide form and further fermenting them into short-chain fatty acids. Since 
humans evolved without the enzymes to carry out this function on our own, this 
mutualistic relationship allows the host organism to acquire carbon and energy while the 
microbes are protected in an anoxic environment and are provided with glycans as a fuel 
source (9).  
 In 2004, Backhed et al. were among the first to investigate the potential of the gut 
microbiota as an environmental factor that could be regulating fat storage through an 
integrated host pathway. Backhed and his team experimented using male B6 mice 8- to 
10- weeks of age. They compared B6 mice raised in the absence of microorganisms (GF) 
to that of mice containing a microbiota since birth (CONV-R). Their findings showed that 
although CONV-R mice consumed 29% less standard rodent chow than the GF mice, 
CONV-R mice were observed to have 42% more total body fat, as well as 47% greater 
weight in epididymal fat pads. In addition, Backhed and his collogues found that within 
14 days of conventionalization of GF B6 mice (using normal microbiota obtained from 
the cecum of CONV-R mice) there was a 60% increase in body fat content and an 
increased insulin resistance regardless of having reduced food intake. Backhed and his 
team discovered the mechanism causing the additional body fat was an increase in the 
absorption of monosaccharides promoted by the gut microbiota, suggesting that the gut 
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microbiota is a crucial environmental factor affecting energy accumulation and storage in 
the host (10).   
 When comparing the mouse gut microbiota to that of a human it has been found 
that the majority of species are unique to the mouse, but they are comparable at the 
phylum classification with Firmicutes and Bacteroidetes dominating (11). Since the 
composition of the mice microbiome is inherited from the mother, Ley et al. wanted to 
see how obesity could affect the diversity occurring in the gut. C57BL/6J ob/+ mothers 
and their offspring (ob/ob, ob/+, and +/+) were all fed the same polysaccharide rich diet.  
Ley and his team discovered that when comparing the obese mice to the lean, the ob/ob 
animals showed a 50% reduction in the quantity of Bacteroidetes and an equivalent 
increase in Firmicutes (11). This finding demonstrates how obesity seems to be affected 
by the shifting of the dominating phylum in the gut, but was unsuccessful at showing 
further insight into the composition and distribution of the species of each phylum of 
these bacteria. 
Probiotics are live yeast and bacteria that have been thought to be advantageous 
for health, especially for the health of the gut, and can be found in foods, as dietary 
supplements and in skin care creams. The World Health Organization defines probiotics 
as “live microorganisms which when administered in adequate amounts confer a health 
benefit on the host” (12). In recent years prebiotics have become an emerging area of 
interest for their potential effect on the gut microbes. Prebiotics are dietary fibers that 
have been shown to be beneficial fuel source for the growth and reproduction of the 
bacterial microflora. The Food and Agriculture Organization of the United States (FAO) 
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defined a prebiotic as “a non-viable food component that confers a health benefit on the 
host associated with modulation of the microbiota” (13). 
Phylum	  Fimicutes	  	  
The phylum Firmicutes is the largest group of bacteria because it is dominated by 
very successful and diverse generas. Firmicutes mainly stain gram-positive due to their 
thick peptidoglycan cell made of protein and carbohydrates that give structure and 
protection from osmotic stress. There is 2,850 species to date within the phylum 
Firmicutes separated into seven classes: the Erysipelotrichia, the Negativicutes, the 
Limnochordia, the Tissierellia, the Thermolithobacteria, the Clostridia and the Bacilli. 
Firmicutes are further divided and categorized by their G+C nucleotide ratio. The 
percentage of G+C determines if a group is considered a “low G+C” or a “high G+C” 
Firmicutes. Some Firmicutes have the ability to form an endospore. An endospore is a 
resistant cell usually produced under stressful conditions. Unlike the oxygen loving 
Bacilli, The Clostridium class contains many anaerobic species. These species have 
different methods for obtaining energy without oxygen, mainly through fermentation. 
Recently, research has been focused on the multiple species within the Clostridium class 
that is anaerobic and has been found to be butyrate-producing, an important and preferred 
energy source for the colonic epithelial cells and have shown to help maintain colon 
health (14). The phylum Firmicutes is a used in many different industries including 
ecology, medicine, agriculture and food production to name a few, making them a major 
area for investigation (15).  
Roseburia	  intestinalis	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 Species Roseburia intestinalis (R. Intestinalis) are members of the phylum 
Firmicutes, class Clostridia, order Clostridiales, Family Lachnospriaceae, and genus 
Roseburia (16). The genus Roseburia was named in honor of Theodor Rosebury, a 
bacteriologist who has been called the “Grandfather of Modern Oral Microbiology” (17).  
Along with RI, there have been five species discovered in this genus. RI and the other 
species in the Roseburia genus are characterized by being Gram-positive and anaerobic, 
having a curved rod shape, low G+C content, have the ability to convert SCFAs to 
produce butyrate and exhibit motility by means of subterminal flagella (18).  
   Roseburia clusters have been predicted to be around 3 to 15% of the total 
bacterial count found in a healthy gut (19). Recent research has found a link between 
Roseburia spp. and overall gut health, including irritable bowel syndrome (IBS), 
inflammatory bowel disease, and colon cancer (20). Van den Abbeele et al. developed a 
dynamic in vitro gut model that has the ability to stimulate luminal and mucosal gut 
microbes. These researchers found that RI specifically colonized mucins and the butyryl-
CoA:acetate-CoA transferase gene sequences belonged to different species in the luminal 
than those colonizing the mucins. These findings suggest that mucosal butyrate producers 
may be helpful in treating GI diseases by increasing the butyrate bioavailability because 
the butyrate is produced close to the epithelium (21).             
  Specifically in ulcerative colitis (UC), studies have found a decrease in the 
prominent butyrate producers, such as RI, has been correlated to a reduction in short 
chain fatty acid concentrations.  Kumari et al. wanted to look at the interaction between 
butyrate producing bacteria and butyrate concentrations in UC patients when compared to 
that of control individuals. Kumari and colleagues discovered that, when compared to the 
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control, the nonhealthy patients exhibited decreased butyrate concentrations and well as 
decreased butyrate producers. They suggest the reduction of butyrate producers and in 
turn reduction in butyrate can lead to a decreased supply of energy to the colon and can 
eventually lead to GI problems (22).  
OBJECTIVE	  
The objective of the current study was to determine the optimal growth conditions 
for R. Intestinalis by adding different concentrations of SCFAs and prebiotics, and to 
determine the effects of environmental factors including pH, bile salts, and antibiotics, as 
well as effects storage conditions on the survivability of R. Intestinalis. 
MATERIALS	  AND	  METHODS	  
General	  Culturing	  	  
  
 Roseburia intestinalis was purchased from DSMZ (Leibniz Institute DSMZ, 
Germany). General culture was done in PYG media with the addition of SCFAs 
according to DSMZ instructions (23) under anaerobic conditions using Hungate roll tube 
method, N2 gas, and anaerobic indicator Resazurin (ACROS, Fair Lawn, NJ) at 0.5mg/L. 
R. Intestinalis was transferred into PYG Hungate tubes using 1 mL syringe with 26G 
needle (BD, Franklin Lakes, NJ) and incubated at 37°C.  
PCR	  Amplification	  and	  Gel	  Electrophoresis	  
 
DNA extraction was done using QIAmp DNA Mini Kit (Qiagen, CA) according 
to the manufacture’s instructions. Primers were designed using the NCBI database from 
R. Intestinalis’s 16s rDNA (Table 1).  Eppendorf© thermocycler (Hauppauge, NY) was 
used to run the PCR. 12.5 µl Sigma ReadyMix™ RedTaq© PCR Reaction Mix (Foster, 
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CA) 0.1µM of each primer, 2 µl DNA template, and PCR water was added to a total 
volume of 25 µL. Denaturation was carried out at 94°C for five minutes, 60°C for 2 
minutes and 72°C for 2 minutes followed by 29°C cycles of 94°C for 2 minutes 60°C for 
30 seconds and 72°C for 2 minutes for amplification, and a final cycle step of 72°C for 
10 minutes (24). A 1.5% agarose gel was prepared in 1x Tris-Borate-EDTA buffer and 
was used for gel electrophoresis. Thermo Scientific© GeneRuler Ultra Low Range DNA 
Ladder (Carlsbad, CA) was used as a standard. SYBR© Green stain (Carlsbad, US) under 
Bio-rad© Imager (Hercules, CA) was to examine final results.  
Growth	  Conditions	  
Short	  Chain	  Fatty	  Acids	  
 
 R. Intestinalis was inoculated into Hungate tubes of PYG with varying SCFAs. A 
SCFA mixture of 33 mM acetate (Sigma Aldrich, St. Louis, MO) with 9 mM propionate 
(Sigma Aldrich, St. Louis, MO) suggested by the manufacturer (Leibniz Institute DSMZ, 
Germany) was used for routine culturing. Additionally, PYG tubes containing 33 mM, 
66mM, and 132 mM acetate, alone, were tested. Tubes were incubated at 37 °C for six 
hours with turbidity measurement taken every half hour. Turbidity value was determined 
using a SIEMENS© turbidity meter (West Sacramento, CA) at 595 nm.  
Prebiotics	  
R. Intestinalis was inoculated into Hungate tubes of PYG with various prebiotics. 
0.5% each of isomaltooligosaccharide (Raw Indulgence LTD, NY), Benefiber 
(Parsippany, NJ) guar gum (Good Gut Solution Company, San Diego, CA), carboxy 
methylcellulose GlaxoSmithKline, Moon Township, PA) oligo-chitosan 95% Xian Lukee 
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Bio-Tech Co., China), galactooligosaccharide (Quantum HI-tech Biological Co. Ltd, 
China), xylooligosaccahride (Quantum HI-tech Biological Co. Ltd, China), 
fructooligosaccharide (Quantum HI-tech Biological Co. Ltd, China), and the positive 
control of glucose (Acros, NJ)were used. Tubes were incubated at 37 °C for six hours 
with turbidity measurement taken every half hour. Turbidity value was determined using 
SIEMENS© turbidity meter at 595 nm.  
Survivability	  Conditions	  
pH	  
 
R. Intestinalis was inoculated into Hungate tubes of PYG with varying pH. pH 2, 
3, 4, 5, 6, 7, 8, 9, and 10 were tested. PYG’s standard pH is 7.04.  Cysteine (Fischer 
Scientific, Fair Lawn, NJ) was added to lower pH while Sodium Bicarbonate 
(Mallinckrodt Chemicals, Phillipsburg, NJ) was added to increase the pH. pH was found 
using Oakton© pH 700 Bench Meter (Vernon Hills, IL). Tubes were incubated at 37 °C 
for 24 hours with turbidity measurement taken at half hour, one hour, four hours and 24 
hours to measure survivability as well as find the optimal pH for growth. Turbidity value 
was determined using SIEMENS© turbidity meter at 595 nm.   
Bile	  Salts	  
R. Intestinalis was inoculated into Hungate tubes of PYG with varying 
concentrations of bile salts  (Fisher Science Education bile salts, Nazareth, PA). 0.1 g/L, 
0.5 g/L, 1.0 g/L, and 5.0 g/L were used. A negative control containing no bile salt was 
used for comparison. Tubes were incubated at 37 °C for four hours with turbidity 
measurement taken at time zero, two hours and four hours to mimic the amount of 
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exposure in vivo. Turbidity value was determined using SIEMENS© turbidity meter at 
595 nm. At 4 hours, samples were taken from each tube and serial diluted using 
phosphate buffer for further plating using PYG agar (Sigma Aldrich, St. Louis, MO) 20 
µL of each bile salt concentration and negative control were plated onto Fischer Scientific 
100 mm x 15 mm plates and put into anaerobic chamber BBL Gas Pak before being 
incubated at 37 °C for 24 hours. After growth CFU was counted to check viability. 
Antibiotics	  
R. Intestinalis was inoculated onto a 48-well plate (Costar, Corning, NY) 
containing PYG with various antibiotics. 10 µg/mL and 20 µg/mL of each Azithromycin 
(Sigma Aldrich, St. Louis, MO), Sulfamethoxzaole (Sigma Aldrich, St. Louis, MO), 
Oxytetracyclin (Sigma Aldrich, St. Louis, MO), Trimethoprim (Sigma Aldrich, St. Louis, 
MO), Erythromycin (Sigma Aldrich, St. Louis, MO), and Ciprofloacin (Sigma Aldrich, 
St. Louis, MO) were used. A blank of just PYG without R. Intestinalis or antibiotics, and 
a negative control containing PYG and R. Intestinalis without antibiotics was used for 
comparison. The plate was incubated at 37 °C for six hours in Perkin Elmer HTS 800 
Bioassay Reader, and absorbance measurement was taken every hour at 595 nm.  
Characterization	  Methods	  
Generation	  Time	  
R. Intestinalis was inoculated into Hungate tubes of PYG and incubated at 37 °C. 
20 µL sample was taken at time zero and four hours and plated onto agar plates and put 
into anaerobic chamber before being incubated at 37 °C for 24 hours. After growth CFU 
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was counted and used in the generation time equation to establish R. Intestinalis’s 
generation time (below) where log is the logarithm of the base (25). 
 
Generation Time =  _______Duration (minutes or hours)                     ______ 
                                (3.3)(log(Final Concentration)−log(Initial Concentration)) 
 
 
Growth	  Curve	  	  	  	  	  
R. Intestinalis was serially diluted and inoculated onto a 48-well plate (Costar, 
Corning, NY) containing PYG. The plate was incubated at 37 °C for 12 hours in 
microplate reader and absorbance measurement was taken every hour at 595 nm. 20 µL 
sample was taken after lag phase during the exponential growth phase determined by 
increasing absorbance values. CFU were counted and plotted against absorbance using 
Microsoft Excel (Microsoft Corporation, Redmond, WA) to generate an absorbance 
curve. 
Processing	  Methods	  
Freeze	  Drying	  
 
 R. Intestinalis was inoculated into 2.5 L of PYG and incubated at 37 °C for 12 
hours. Media was centrifuged and excess media was disposed of. A 10% sucrose media 
solution was added for protection. Liquid nitrogen was used to flash freeze the RI and it 
was stored in -80° C freezer overnight. Labconco Triad freeze dryer was used. The 
sample was kept in the freezer dryer for 3 days until sample was completely dried. 
Freeze-dried samples are stored in -20° C for future use. Freeze-dried samples were 
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reconstituted into PYG media and incubated at 37° C for one hour before being plated 
using PYG agar to ensure the bacteria is still viable after freeze drying method. 
Encapsulation	  
 
 Freeze-dried R. Intestinalis was encapsulated according to method from 
Sohail et al. (26) (adapted for use by colleague Jiarun Cui). R. Intestinalis was 
encapsulated using 1% Sodium Alginate (Acros NJ), 1% Casein (Hard Eight Nutrition, 
Henderson, NV) , 0.5% prebiotic (guar gum) to 3% bacteria. Solution is dropped into 
Calcium Chloride (Sigma Aldrich, St. Louis, MO) to solidify the bacterial solution. 
Beads were put under hood and allowed to dry overnight. To check viability, 
encapsulated beads and a freeze-dried sample (no encapsulation) were exposed to 
physiological digestive conditions. Beads and freeze-dried samples were added to a 20 
mg/mL Pepsin (Sigma Aldrich, St. Louis, MO) HCL (Sigma Aldrich, St. Louis, MO) 
solution and incubated at 37° C for one hour to mimic gastric digestion. After one hour, 
the mixture is centrifuged and the Pepsin HCL is disposed of. A 33mg/mL solution of 
Enteric Digestive Fluid was immediately added incubated at 37° C for two hours to 
mimic enteric digestion. Beads are homogenized using to release the bacteria and plated 
using PYG agar. Plates were put into anaerobic chamber before being incubated at 37 °C 
for 24 hours. After growth CFU was counted to check viability and to compare 
survivability in each storage condition. 
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RESULTS	  AND	  DISCUSSIONS	  
Gel	  Electrophoresis	  
 Figure 1 shows the gel electrophoresis ran with the R.intestinalis DNA primers 
against the low range DNA ladder. Only primer one showed a visible band between 150 
bp and 200 bp, whereas the band is slightly closer to the 150 bp band in confirmation 
with the 159 bp primer one has. This gel electrophoresis is able to show the DNA that 
was extracted and amplified does belong to R. intestinalis.  
	  
Low	  range	  
DNA	  ladder	   
Primer	  #1 
	  
	  
300	   
	  
200	   	  
150	   
bp 
Figure 1- Agarose gel showing the amplification and identification of 
R.intestinalis 16S rDNA when compared to a low range DNA ladder   
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Short	  Chain	  Fatty	  Acids	  
 
 From literature research R.intestinalis has been shown to convert acetate to 
butyrate, a desired end product. Figure 2 is examining the growth of R.intestinalis at 
different concentrations of acetate when compared to the literature SCFA 
recommendation for growth, an acetate (33 mM) and propionate (9 mM) mixture, to see 
if R.intestinalis had the ability to grow in acetate alone and at what concentration yielded 
the most growth. From time 30 minutes to 150 minutes all SCFA conditions showed 
similar growth as a result of the lag phase. At 180 minutes the SCFA mixture and 66 mM 
acetate begin to increase growth while 33 mM acetate and 132 mM acetate do not show 
increased growth at the same rate. 132 mM acetate seemed to cause a longer lag time 
before growth was seen at 270 minutes. Too much acetate in the media may have made it 
harder for the R.intestinalis to utilize the other crucial nutrients in the media increasing 
the time it took to reach their exponential growth phase. SCFA mixture and 66 mM 
acetate were found to be very comparable for the optimal growth condition, with SCFA 
showing slightly increased growth near the end. Since R.intestinalis converts acetate 
through the butyryl-CoA:acetate-CoA transferase gene, it was important to see how 
different concentrations of acetate alone could affect growth when compared with the 
literature recommendation for future studies trying to optimize the butyrate conversion 
potential. 
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Figure 2- Growth of R.intestinalis at varying concentrations of acetate and 
compared to a SCFA mixture of acetate and propionate to identify the optimal 
condition. 
 
Prebiotics	  
 
 Figure 3 examines the effect of prebiotics on the growth of R.intestinalis as 
compared to glucose alone. Table 1 gives the full names of the prebiotics used and a short 
description of what they are. As shown in Figure 3, the lag phase lasted from 30 minutes 
to around 150 minutes in accordance with previous results. At 180 minutes three 
prebiotics begin to show growth similar to glucose, guar gum, isomaltooligosaccharide, 
and fructooligosaccharide, respectively. 
 Upon further research into these prebiotics it was discovered that guar gum is 
composed of galactose and mannose, which are both epimers of glucose. Galactose and 
mannose have the same chemical formula as glucose but are stereochemically different at 
carbon-4 and carbon-2 configuration, respectively. Because of this, R.intestinalis most 
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likely is able to utilize the guar gum in the same manner at which it utilizes glucose. 
Isomaltooligosaccharide is an oligomer of glucose. R.intestinalis would be able to utilize 
the IMO exactly the same as glucose but it may take more energy to break the bonds to 
use the glucose and in turn cause slightly less growth than glucose alone.  
 
Table 1 – Full names and Descriptions of prebiotics used to see which provided 
optimal growth to R.intestinalis 
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Figure 3 – Effects of prebiotics on the growth of R.intestinalis as compared to 
glucose alone.  
 
pH	   	  
Error! Reference source not found. shows the optimal growth of R.intestinalis 
at varying pH. Initial absorbance taken at time zero shows a higher absorbance as the pH 
increases due to the addition of sodium bicarbonate. pH 2, 3, 4, and 5 all had very similar 
growth making the plot line overlap for each. When tested these pH plot line stayed 
constant and were not found to be the optimal growth condition. pH 10 had the highest 
absorbance initially due to the addition of the most sodium bicarbonate. pH 10 was also 
found to inhibit the growth of R.intestinalis and the plot line stayed constant. At pH 6 
growth begins but was not found to be the optimal condition. At pH 7, 8, and 9 growth of 
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R.intestinalis was found to be optimal with pH 8 showing the highest absorbance during 
the exponential phase. Freeze dried bacteria was used and most likely caused an increase 
in lag time. At four hours there was not a significant difference between the varying pH 
so additional time was given to find the optimal pH for growth.  
Figure 4 – Growth of R.intestinalis at varying pH 2, 3, 4, 5, 6, 7, 8, 9 and 10 
 
Bile Salts   
Figure 5 is examining the effect of various concentrations of bile salts on the 
survivability of R.intestinalis. As a result of the digestion process, these bacteria will be 
vulnerable to exposure of bile salts and to be a successful probiotic they will have to 
withstand the 400 mL to 800 mL that is produced daily (27). From this figure it can be 
examined that, when compared with the negative control, R.intestinalis shows the best 
survivability at the lowest concentration, 0.1 g/L. Bacteria was only plated for 240 
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minutes to mimic the exposure time that would occur in vivo. As the concentration of bile 
salts increased the survivability of R.intestinalis decreased. Although there is not a 
significant amount of growth occurring at these concentrations of bile salts, it cannot be 
assumed the R.intestinalis are no longer viable. To check the viability of the R.intestinalis 
at the different concentrations of bile salts a sample of each concentration was plated with 
PYG agar at time zero and 240 minutes (Figure 6). CFU counts showed that for each 0.1 
g/L, 0.5 g/L, and 1.0 g/L the R.intestinalis were still viable and showed growth when 
compared to the CFU count at time zero. Concentration 5g/L showed no growth when 
compared with time zero. These results showed that although increasing the 
concentration of bile salts did not increase the growth of R.intestinalis, plating the 
bacteria to further check their viability showed they could survive in concentrations up to 
1.0 g/L 
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Figure 5 –Survivability of R.intestinalis at various concentrations of bile salts.  
Figure 6 – Viability CFU check of R.intestinalis after incubated with various  
concentrations of bile salts (0-5.0 g/L). 
Antibiotics	  
 Various antibiotics at 10 µg/mL and 20 µg/mL were tested for their effect on the 
survivability of R.intestinalis for the potential use as a probiotic to repopulate the gut 
while on antibiotics. Azithromycin, Sulfamethoxzaole, Oxytetracycline, Trimethoprim, 
Erythromycin, and Ciprofloacin were used. Table 3 gives the mode of action of each 
antibiotic used.  
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Table 2 - Descriptions of antibiotics modes of action tested on R.intestinalis  
 
 
 
 
 Figure 7 shows the growth of R.intestinalis in the presence of the antibiotic 
Azithromycin. From this figure it can be seen that when compared to the control 
containing no antibiotics, R.intestinalis is not sensitive to Azithromycin. Since 
Azithromycin is a broad but shallow antibiotic (28) that treats only some gram positive 
and negative bacteria R.intestinalis may not fall into the scope of this antibiotic and 
therefore shows no sensitivity.  
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Figure 7 – Survivability of R.intestinalis in the presence of the antibiotic 
Azithromycin at 10 µg/mL and 20 µg/mL when compared to a negative control. 
  
 Figure 8 shows that R.intestinalis is not sensitive to Sulfamethoxzaole. 
Sulfamethoxzaole’s mode of action is to prevent folic acid synthesis in bacteria that 
require synthesizing their own folic acid rather than utilizing their host’s folic acid (29). 
It is likely that R.intestinalis does not synthesize folic acid and therefore falls outside of 
this antibiotics mode of action, although research has not yet been done to confirm 
R.intestinalis’ mechanism for up taking folic acid. 
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Figure 8 - Survivability of R.intestinalis in the presence of the antibiotic 
Sulfamethoxazole at 10 µg/mL and 20 µg/mL when compared to a negative control. 
 
Figure 9-12 show the sensitivity of R.intestinalis in the presence of 
Oxytetracycline, Trimethoprim, Erythromycin, and Ciprofloacin, respectively. 
R.intestinalis was found to be sensitive to these antibiotics and increased growth was not 
observed. Oxytetracycline’s mode of action is to affect the way bacteria synthesize and 
produce proteins (30). R.intestinalis was found to be the most sensitive to this antibiotic 
at both concentrations tested. 
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Figure 9 - Survivability  of R.intestinalis in the presence of the antibiotic 
Oxytetracycline at 10 µg/mL and 20 µg/mL when compared to a negative control. 
  
R.intestinalis was also found to be sensitive to the antibiotic Trimethoprim 
although it is not recommended for use on anaerobic bacteria. Upon further investigation, 
Trimethoprim interferes with the action of dihydrofolate reductase and the anaerobic 
bacteria that have been shown sensitive to Trimethoprim fall in different classes than 
R.intestinalis (31). As a result, anaerobic bacteria that fall into the class Clostridium may 
be sensitive to Trimethoprim’s mode of action and as a result growth of  R.intestinalis in 
its presence cannot be observed.  
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Figure 10 - Survivability  of R.intestinalis in the presence of the antibiotic 
Trimethoprim at 10 µg/mL and 20 µg/mL when compared to a negative control. 
 
Additionally, R.intestinalis was found to be sensitive to the antibiotic 
Erythromycin. Erythromycin mode of action is not yet understood, but it does show 
bacteriostatic activity (32). R.intestinalis may be sensitive to the bacteriostatic activity 
observed from Erythromycin and in turn is why increased growth is not observed when 
compared to the negative control although there is slight growth at 6 hours. Over time, 
without additional doses, surviving R.intestinalis may be able to overcome the 
bacteriostatic effects and begin to repopulate. 
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Figure 11 - Survivability  of R.intestinalis in the presence of the antibiotic 
Erythromycin at 10 µg/mL and 20 µg/mL when compared to a negative control. 
 
Finally, R.intestinalis was found to be sensitive to Ciprofloacin when compared to 
the negative control. Although R.intestinalis was found to be sensitive to Ciprofloacin, it 
did appear to have very slight growth in the beginning before no growth is observed. 
Ciprofloacin’s mode of action is to inhibit the enzymes topoisomerase II and IV (33). 
Ciprofloacin’s mode of action may take a couple generations of growth before taking full 
inhibitory effect on the R.intestinalis and may be why slight growth is seen in the 
beginning before no increased growth is obsereved. 
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Figure 12 - Survivability  of R.intestinalis in the presence of the antibiotic 
Ciprofloacin at 10 µg/mL and 20 µg/mL when compared to a negative control. 
 
Generation	  Time	  and	  Growth	  Curve	  
 Table 4 shows the generation time was found using the generation time equation 
from CFU count over four hours of growth. R.intestinalis generation time was found to 
be 30.5 minutes. 
Table 3 – Generation time of R.intestinalis over 4 hours calculated using the 
generation time equation. Generation time found to be 30.5 minutes. 
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Figure 13 is the absorbance curve that was generated from absorbance readings 
plotted against their respective CFU counts. The equation generated can be used to find 
the CFU of R.intestinalis when and absorbance is found. The R2 value is 0.99715 
signifying that this model fits the data and is a good tool for finding CFU. 
 
 
 
 
 
 
 
 
 
 
 
Figure 13 – Absorbance curve of R.intestinalis. R2 value is 0.99715 showing model is 
a good fit of the data and can be used to find the CFY of R.intestinalis when 
absorbance is taken 
 
Encapsulation	  
For R.intestinalis to be a successful probiotic it needs to survive the stomach and 
GI conditions in order to repopulate the gut. pH 2 did not show growth and because of 
this, encapsulation was done for protection. Error! Reference source not found. 
compared the growth of encapsulated freeze-dried and non-encapsulated freeze dried 
R.intestinalis after being exposed to physiological digestive conditions. Trial 1 shows no 
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significant difference in the growth of R.intestinalis when comparing encapsulated to not 
encapsulated. A second trial was conducted and similar results were seen, there was not 
increased survivability of the R.intestinalis in the encapsulated samples. From these 
results it can be hypothesized that R.intestinalis may grow in physiological digestive 
conditions without encapsulation. Since pH samples were not plated to check viability, it 
cannot be assumed that just because there was no growth in pH 2 that would make the 
R.intestinalis unviable. Further investigation into R.intestinalis’ viability at low pH and 
survivability in physiological digestive conditions will need to be conducted to see the 
best vehicle for distributing R.intestinalis as a potential probiotic. 
 
CONCLUSION	  
This study focused on the optimal growth, survivability, and storage conditions of 
a novel potential probiotics R.intestinalis.  When SCFAs were added, R.intestinalis was 
found to grow the best at 66 mM acetate, but did show similar growth at 33 mM acetate 
with the addition of 9 mM propionate. The prebiotics guar gum and 
isomaltooligosaccharide showed similar growth to that of glucose. Survivability was 
examined and growth was observed in pH 6 – pH 9. R.intestinalis was found survive 
under low bile salt conditions but was not viable at concentration 5 g/L. Also, 
R.intestinalis showed no sensitivity to Azithromycin and Sulfamethoxazole. 
Encapsulation did not increase the survivability of the R.intestinalis when exposed to 
physiological digestive conditions and compared to samples that were not encapsulated. 
Further investigation into R.intestinalis and eventual animal experimentation may show 
the beneficial effects this novel bacterium could have as use in a probiotics. 
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Obesity and diabetes is an epidemic of increasing concern. Certain novel bacteria 
have been found to be an aid in reversing some of the mechanisms associated. This study 
focused on investigating the optimal stability conditions for R.intestinalis that can 
associate with an increase in growth. First, environmental conditions were tested to find 
the optimal conditions associated with each. Once growth conditions were found, 
generation time was calculated and various prebiotics were used to investigate a potential 
for additional growth. Next, common antibiotics were tested to see if the R.intestinalis 
could still show growth when exposed. Large batches of R.intestinalis were grown and 
freeze dried for storage and further experimental purposes. The freeze-dried R.intestinalis 
was encapsulated and reconstituted to check for viability. Finding the optimal conditions 
for growing R.intestinalis and using the encapsulation technique to protect the 
R.intestinalis from unfavorable environmental conditions could lead to the potential for 
R.intestinalis to become a probiotic that could help people suffering from adverse GI 
diseases and symptoms as well as decrease GSIS due to excess acetate.  
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